Cargando…

Irinotecan-Induced Steatohepatitis: Current Insights

The hepatotoxicity of irinotecan is drawing wide concern nowadays due to the widespread use of this chemotherapeutic against various solid tumors, particularly metastatic colorectal cancer. Irinotecan-induced hepatotoxicity mainly manifests as transaminase increase and steatosis with or without tran...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Jun, Zhang, Jing, Zhang, Chengliang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542761/ https://www.ncbi.nlm.nih.gov/pubmed/34707997 http://dx.doi.org/10.3389/fonc.2021.754891

Ejemplares similares

Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma
por: Zhu, Jia, et al.
Publicado: (2022)

Irinotecan Plus Doxorubicin Hydrochloride Liposomes for Relapsed or Refractory Wilms Tumor
por: Wang, Juan, et al.
Publicado: (2021)

Recent Insights Into the Multiple Pathways Driving Non-alcoholic Steatohepatitis-Derived Hepatocellular Carcinoma
por: Takakura, Kazuki, et al.
Publicado: (2019)

Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world study
por: Gupta, Amol, et al.
Publicado: (2023)

Effectiveness and safety of capecitabine, irinotecan and panitumumab in advanced colorectal cancer
por: Yip, Pui Lam, et al.
Publicado: (2023)

Establishment and Characterization of an Irinotecan-Resistant Human Colon Cancer Cell Line
por: Wu, Zhuo-Xun, et al.
Publicado: (2021)

Microbiota-Host-Irinotecan Axis: A New Insight Toward Irinotecan Chemotherapy
por: Yue, Bei, et al.
Publicado: (2021)

Risk factors for irinotecan-induced liver injury: a retrospective multicentre cross-sectional study in China
por: Han, Jun, et al.
Publicado: (2023)

Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan
por: Yu, Kenneth H., et al.
Publicado: (2021)

Fibrosis-4 index is associated with the risk of hepatocellular carcinoma in patients with cirrhosis and nonalcoholic steatohepatitis
por: Albhaisi, Somaya, et al.
Publicado: (2023)

Cisplatin and Irinotecan as First-Line Chemotherapy for Previously Untreated Metastatic Thymic Carcinoma: Updated Analysis
por: Fukuda, Akito, et al.
Publicado: (2022)

A Case of Metastatic Urachal Carcinoma Treated With FOLFIRI (irinotecan and 5-Fluorouracil/leucovorin) Plus Bevacizumab
por: Kanamaru, Tomohiro, et al.
Publicado: (2014)

Fluorouracil Supplemented With Oxaliplatin or Irinotecan for Solid Tumors: Indications From Clinical Characteristics and Health Outcomes of Patients
por: Qingwei, Zhao, et al.
Publicado: (2020)

Irinotecan-Induced Dysarthria
por: Dressel, Albertine J., et al.
Publicado: (2012)

Dehydroepiandrosterone (DHEA) Sensitizes Irinotecan to Suppress Head and Neck Cancer Stem-Like Cells by Downregulation of WNT Signaling
por: Li, Li-Jie, et al.
Publicado: (2022)

Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial
por: Qu, Jinglei, et al.
Publicado: (2023)

Doxorubicin-Induced Cognitive Impairment: The Mechanistic Insights
por: Du, Jiajia, et al.
Publicado: (2021)

Copper metabolism and hepatocellular carcinoma: current insights
por: Zhou, Cheng, et al.
Publicado: (2023)

A Retrospective Analysis of the Effect of Irinotecan-Based Regimens in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
por: Suo, Jiaojiao, et al.
Publicado: (2021)

A Chart Review on the Feasibility and Safety of the Vincristine Irinotecan Pazopanib (VIPaz) Association in Children and Adolescents With Resistant or Relapsed Sarcomas
por: Russo, Ida, et al.
Publicado: (2020)

Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter Study
por: Su, Yung-Yeh, et al.
Publicado: (2022)

Bevacizumab-Irinotecan combination therapy in recurrent low-grade glioma, previously treated with chemo-radiotherapy: a case report
por: Castelli, Barbara, et al.
Publicado: (2023)

UGT1A1 Allele Test Not Only Minimizes the Toxicity But Also Maximizes the Therapeutic Effect of Irinotecan in the Treatment of Colorectal Cancer: A Narrative Review
por: Li, Yaoyuan, et al.
Publicado: (2022)

Current insights into the regulation of programmed cell death by TP53 mutation in cancer
por: Su, Yali, et al.
Publicado: (2022)

Anticancer properties of sulforaphane: current insights at the molecular level
por: Asif Ali, Muhammad, et al.
Publicado: (2023)

Corrigendum: Current insights into the regulation of programmed cell death by TP53 mutation in cancer
por: Su, Yali, et al.
Publicado: (2022)

Phase I Study of Celecoxib with Concurrent Irinotecan, Cisplatin, and Radiation Therapy for Patients with Unresectable Locally Advanced Non-Small Cell Lung Cancer
por: Komaki, Ritsuko, et al.
Publicado: (2011)

Immunotherapy and Targeting the Tumor Microenvironment: Current Place and New Insights in Primary Pulmonary NUT Carcinoma
por: Li, Xiang, et al.
Publicado: (2021)

Spontaneous Aortic Haematoma in a Patient Receiving Adjuvant Folinic Acid, 5-Fluorouracil, Irinotecan, and Oxaliplatin Chemotherapy Following Resection of a Pancreatic Adenocarcinoma
por: Dacie, Ruth, et al.
Publicado: (2020)

Effectiveness and Cost-Utility Analysis of Different Doses of Irinotecan Plus Bevacizumab in Patients With Metastatic Colorectal Cancer: A Long-Term and Prospective Cohort Study
por: Shi, Hon-Yi, et al.
Publicado: (2022)

Case report: Irinotecan-induced interstitial lung disease in an advanced colorectal cancer patient resurfacing decades after allogeneic bone marrow transplantation for aplastic anemia; a case report and narrative review of literature
por: Baba, Keisuke, et al.
Publicado: (2023)

Randomized double-blind, placebo-controlled multicenter phase III study of prevention of irinotecan-induced diarrhea by a probiotic mixture containing Bifidobacterium BB-12(®) Lactobacillus rhamnosus LGG(®) in colorectal cancer patients
por: Mego, Michal, et al.
Publicado: (2023)

Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer
por: Perrone, Emanuele, et al.
Publicado: (2020)

Herbal Medicines for Irinotecan-Induced Diarrhea
por: Tang, Liu, et al.
Publicado: (2019)

New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics
por: Thakur, Neha, et al.
Publicado: (2023)

Systematic evaluation of irinotecan-induced intestinal mucositis based on metabolomics analysis
por: Yu, Qing-Qing, et al.
Publicado: (2022)

Irinotecan-Induced Serpentine Supravenous Hyper-Pigmentation
por: Gaurav, Vishal, et al.
Publicado: (2022)

An Insight on the Pathways Involved in Crizotinib and Sunitinib Induced Hepatotoxicity in HepG2 Cells and Animal Model
por: Guo, Lin, et al.
Publicado: (2022)

Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
por: Yang, Liuting, et al.
Publicado: (2018)

Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status
por: Roy, Partho Pratik, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2i069t99t57nqojb9cisvtrr0q